CSI Market
Sign In | Register

Stemline Therapeutics Inc (STML) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access STML Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Stemline Therapeutics Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2020)
3 Months 		(Dec 31 2019) (Sep 30 2019) (Jun 30 2019) (Mar 31 2019)
Operating Activities
Income-21.29
Depreciation & amortization0.01
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.22
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation4.46
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), before Tax, Total0.01
Employee Stock Purchase Plan Compensation Expense0.06
Increase Decrease In Right Of Use Asset Net Operating Lease-
Increase Decrease In Right Of Use Liability Current Portion Operating Lease-0.30
Increase Decrease In Contract With Customer Liability-
Income taxes0.00
Marketable Securities, Gain (Loss), Excluding Other than Temporary Impairments, Total0.00
Increase (Decrease) in Accounts Receivable3.24
Increase (Decrease) in Accounts Payable and Accrued Liabilities-0.12
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.18
Other Working Capital0.01
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.18
Discontinued operations0.00
Net Cash flow from Operating Activities-13.77
Investing Activities
Capital Expenditures-0.01
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities39.32
Payments to Acquire Marketable Securities-10.05
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities29.25
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.02
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock From Espp0.19
Finance Lease Principal Payments-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.22
Effect of exchange rate on cash flow-0.03
Discontinued operations0.00
Free Cash Flow-13.79
Total Cash Flow15.67
4 historic quarters locked

Sign in to unlock the full Stemline Therapeutics Inc cash flow history.

Sign In Create Free Account

About STML Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.